Karyopharm Therapeutics Inc.

Good morning. My name is Ludi, and I will be your conference operator today. At this time, I would like to welcome everyone to the Career Forum Therapeutics Third Quarter 2025 Financial Results Conference Call. There will be a question and answer session to follow. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Brandon Strong, Senior Vice President, Investor Relations and Corporate Communications. Please go ahead.

Good morning. And thank you all for joining us on today's conference call to discuss CarioFarm's third quarter 2025 financial results and recent company progress. We issued a press release this morning detailing our financial results for the third quarter of 2025. This release, along with a slide presentation that we will reference during our call today, are available on our website. For today's call, as seen on slide two, I'm joined by Richard, Reshma, Sohania, and Lori who will provide an update on our results for the third quarter of 2025 and discuss recent clinical developments. Before we begin our formal comments, I'll remind you that various remarks we will make today constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995, as outlined on slide three. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those discussed in the risk factor section of our most recent form 10Q or 10K on file with the SEC and in other filings that we may make with the SEC in the future. Any forward-looking statements represent our views as of today only. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change. Therefore, you should not rely on these forward-looking statements as representing our views as of any later date. I'll now turn the call over to Richard. Please turn to slide four.

Thank you, Brendan, and thank you all for joining us today for CarioFarm's Q3 2025 earnings call. As we turn to slide five, I'm pleased to share that this has been a very productive quarter for CarioFarm, one defined by meaningful clinical progress and strengthened financial flexibility, that together set the stage for our next chapter of growth. In Q3, we completed enrollment in our phase three Sentry trial in frontline myelofibrosis, marking a pivotal moment for Keriopharm. Sentry represents a significant opportunity to redefine the standard of care for patients with myelofibrosis through the combination of Selinexor plus Ruxolitinib as a potential all-oral treatment option. With top line results expected in March, we believe this trial could establish a new paradigm for how myofibrosis is treated and further validate the relevance of XB01 inhibition in hematological malignancies. The power of XB01 inhibition is multidimensional. It simultaneously targets multiple pathways that enable malignant cell growth and proliferation. Targeting of these relevant pathways concurrently overcomes the limitations of targeted therapies, such as ruxolitinib, a JAK inhibitor that mostly delivers symptomatic benefits that many consider palliative. This unique and potentially foundational mechanism could establish XPO1 inhibition as a key mechanism in myelofibrosis with further potential across the broader MPN landscape. In October, we made significant progress in strengthening our financial foundation. Through comprehensive refinancing and capital restructuring, we secured approximately $100 million of financial flexibility and additional capital, extending our cash runway into the second quarter of 2026. Turning to our financial performance, our profitable multi-myeloma commercial organization provides a solid foundation on what to build. In the third quarter, we delivered total revenue of $44 million, an increase of 13% year-over-year, and U.S. net product revenue grew 8.5%, reaching $32 million. This growth reflects the continued strength of Exposio in multiple myeloma and the disciplined execution of our commercial and operational teams. Importantly, We delivered this level of growth while continuing to reduce expenses. As we look ahead, our recent financing enables us to continue with focus and conviction around three core priorities. First, advancing our late-stage clinical programs, Sentry and EC042, which we believe have the potential to be truly transformative for patients and the company. Second, driving continued growth across our Expovio franchise. And third, maintaining financial discipline as we execute on our strategy and position CarioFarm for sustained success. Taking together, these underscores the momentum and transformation underway at CarioFarm. We are executing with clarity and purpose as we advance our mission to pioneer innovative cancer therapies that can meaningfully improve the lives of patients and deliver long-term value for all our stakeholders. As our next major milestone is the top-line myofibrosis data from Sentry, we will focus much of today's discussion on the science supporting this program and the significant commercial opportunity ahead. Now, I'd like to turn the call over to Reshma to review our science.